Higher Radiation Dose to Rectal Tumors to Help Avoid Surgery
Tests a higher radiation dose to the tumor in adults with rectal cancer.
Plain-language title generated from the registry record
Registry title: Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients
Key facts
- Where
- Rotterdam, NetherlandsSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with rectal cancer that has not spread widely, who could be treated with the aim of keeping the rectum without surgery.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Rectal adenocarcinoma confirmed under the microscope. On MRI: stage T1-3, N0/N1 (3 or fewer positive lymph nodes near the rectum), no distant spread (MX/M0). Treatment aims to remove all of the disease while keeping the rectum.
- Earlier treatment
- No earlier radiotherapy in the pelvic area and no earlier local removal of the tumor.
- Biomarker or test result
- People with DPD (dihydropyrimidine dehydrogenase) deficiency cannot join. Otherwise no marker is asked for.
Main reasons for not taking part
- Earlier radiotherapy in the pelvic area
- Another cancer now or in the past 3 years (except adequately treated basal cell carcinoma)
- Reasons that rule out (chemo)radiotherapy or surgery
- Lateral lymph nodes, cN2 status, extramural vascular invasion or mesorectal fascia involvement on MRI
- Mucinous tumor on MRI, or earlier local removal of the tumor
Read by machine on 9 November 2026.
Where in Netherlands
- Erasmus MCRotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Claudia Schuurhuizen
- Trial code
- NCT07616297
- Record updated
- 1 June 2026
- Original description
The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.Read full original descriptionShow less
REctal Organ Preservation With a BOost Approach Using CBCT-based Online Adaptive radioTherapy
The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.
Inclusion: Age ≥18 years; Eastern cooperative oncology group (ECOG) performance status ≤2; Histologically confirmed rectal adenocarcinoma; Non-locally advanced rectal cancer, defined as (magnetic resonance imaging (MRI)-based) T1-3, N0/N1 (≤3 positive mesorectal lymph nodes), MX/M0; Indication for curative treatment with organ preservation; Discussed in the multidisciplinary tumor board (MTB); Written informed consent.
Exclusion: Previous radiotherapy in the pelvic area; Other malignancies, except for adequately treated basal cell carcinoma (BCC), at time of inclusion or within 3 years prior to inclusion; Contra-indications for (chemo)radiotherapy or surgery; Prior local excision of the primary tumor; Presence of lateral lymph nodes, cN2 status, extramural vascular invasion (EMVI) or mesorectal fascia involvement as seen on MRI; Mucinous defined tumor on MRI; DPD (dihydropyrimidine dehydrogenase) deficiency; Unable to understand the requirements of the study and to give written informed consent, as determined by the treating physician.